Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates A/S Announces New Hospital as Clinical Routine Customer in Greece

10/25/2021 | 11:42pm EST

ViroGates A/S announces the first order from a new clinical routine customer in Greece. The customer is a hospital located in the Athens area. The hospital is a public hospital with more than 700 beds and is one of Greece's leading university hospitals. The hospital has placed the first order of suPARnostic? TurbiLatex for its Roche cobas 701 system. The hospital has previously also been a participant in the SAVE-MORE COVID-19 study using the suPARnostic? Quick Triage product.


ę S&P Capital IQ 2021
All news about VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More news
Financials
Sales 2020 5,35 M 0,81 M 0,81 M
Net income 2020 -18,7 M -2,84 M -2,84 M
Net cash 2020 33,5 M 5,08 M 5,08 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 488 M 73,9 M 73,9 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float -
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S6.94%74
EXACT SCIENCES CORPORATION-4.07%12 865
GUARDANT HEALTH, INC.-28.64%7 255
BGI GENOMICS CO., LTD.0.55%5 717
SEEGENE, INC.2.95%2 702
INVITAE CORPORATION-29.54%2 436